Review



human/mouse cxcl12/sdf-1 antibody  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Bio-Techne corporation human/mouse cxcl12/sdf-1 antibody
    Human/Mouse Cxcl12/Sdf 1 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 104 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/MAB310/Human%2FMouse+CXCL12%2FSDF-1+Antibody/custom%40mab310%4042990878
    Average 95 stars, based on 104 article reviews
    human/mouse cxcl12/sdf-1 antibody - by Bioz Stars, 2026-11
    95/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Lactylation-associated CXCL12-mediated intercellular communication in rheumatic heart disease valves
    Article Snippet: HP-1 pretreatment with the CXCR4 antagonist AMD3100 (10 μM, 30 min; MedChemExpress, Cat. No. HY-10046). Additional groups included lactate-conditioned medium containing a CXCL12-neutralizing antibody (R&D Systems, Cat. No. MAB310) and recombinant human CXCL12/SDF-1α (R&D Systems, Cat. No. 350-NS) as a positive chemotactic control. Migrated cells were counted in three randomly selected microscopic f

    Control:

    Article Title: Lactylation-associated CXCL12-mediated intercellular communication in rheumatic heart disease valves
    Article Snippet: HP-1 pretreatment with the CXCR4 antagonist AMD3100 (10 μM, 30 min; MedChemExpress, Cat. No. HY-10046). Additional groups included lactate-conditioned medium containing a CXCL12-neutralizing antibody (R&D Systems, Cat. No. MAB310) and recombinant human CXCL12/SDF-1α (R&D Systems, Cat. No. 350-NS) as a positive chemotactic control. Migrated cells were counted in three randomly selected microscopic f

    Chloramphenicol Acetyltransferase Assay:

    Article Title: Lactylation-associated CXCL12-mediated intercellular communication in rheumatic heart disease valves
    Article Snippet: HP-1 pretreatment with the CXCR4 antagonist AMD3100 (10 μM, 30 min; MedChemExpress, Cat. No. HY-10046). Additional groups included lactate-conditioned medium containing a CXCL12-neutralizing antibody (R&D Systems, Cat. No. MAB310) and recombinant human CXCL12/SDF-1α (R&D Systems, Cat. No. 350-NS) as a positive chemotactic control. Migrated cells were counted in three randomly selected microscopic f



    Similar Products

    95
    Bio-Techne corporation human/mouse cxcl12/sdf-1 antibody
    Human/Mouse Cxcl12/Sdf 1 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/MAB310/Human%2FMouse+CXCL12%2FSDF-1+Antibody/custom%40mab310%4042990878
    Average 95 stars, based on 1 article reviews
    human/mouse cxcl12/sdf-1 antibody - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    R&D Systems cxcl12
    Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes in <t>CXCL12,</t> e) Comparison of changes in EPO, f) Comparison of changes in TPO. Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.
    Cxcl12, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/MAB310/Human%2FMouse+CXCL12%2FSDF-1+Antibody/pmc12967180-81-13-33
    Average 94 stars, based on 1 article reviews
    cxcl12 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems mouse monoclonal anti cxcl12 sdf 1
    Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes in <t>CXCL12,</t> e) Comparison of changes in EPO, f) Comparison of changes in TPO. Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.
    Mouse Monoclonal Anti Cxcl12 Sdf 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/MAB310/Human%2FMouse+CXCL12%2FSDF-1+Antibody/pm40615895-77-104-108
    Average 94 stars, based on 1 article reviews
    mouse monoclonal anti cxcl12 sdf 1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems cxcl12 neutralizing antibody
    Fig. 5 <t>CXCL12</t> regulates CD8+ T-cell infiltration after SAH. A: Representative flow cytometric profiles of CD8+ and CD4+ T cells from the cerebral cortex across different groups. The gating strategy is provided in Supplementary Data 1. B: Immunofluorescence staining for CD8+CXCR4+ cells around the cerebral cortex across different groups. Scale bar = 50 μm. C-D: Quantification of CD8+ and CD4+ T cells (n = 6). E: Quantification of CD8+CXCR4+ cells (n = 6). Saline refers to the vehicle-treated control group; CXCL12 refers to the group treated with recombinant CXCL12 protein; CXCL12 Ab indicates the group treated with a CXCL12 neutralizing antibody; and CXCL12 + AMD3100 represents the group cotreated with recombinant CXCL12 and the CXCR4 antagonist AMD3100. **p < 0.01, ****p < 0.0001. ns indicates no significance (p > 0.05)
    Cxcl12 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/MAB310/Human%2FMouse+CXCL12%2FSDF-1+Antibody/pm40270006-91-25-29
    Average 94 stars, based on 1 article reviews
    cxcl12 neutralizing antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes in CXCL12, e) Comparison of changes in EPO, f) Comparison of changes in TPO. Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.

    Journal: Journal of Medical Biochemistry

    Article Title: Randomized controlled trial of intraosseous access vs. intravenous access in traumatic hemorrhagic shock: Effects on inflammation, hematopoiesis, and coagulation

    doi: 10.5937/jomb0-58956

    Figure Lengend Snippet: Impairment of hematopoietic function. a) Comparison of changes in CD34 + , b) Comparison of changes in CFU-GM, c) Comparison of changes in BFU-E, d) Comparison of changes in CXCL12, e) Comparison of changes in EPO, f) Comparison of changes in TPO. Note: 'a' indicates P < 0.05 compared with T0, 'b' indicates comparison with T1, and 'c' indicates P < 0.05 compared with the IV group at the same time.

    Article Snippet: The following indicators were analyzed: IL-1β (DLB50), IL-6 (D6050B), IL-10 (D1000B), HMGB1 (IC1690G), CXCL12 (MAB310), EPO (DEPRU0), and TPO (BAF288): These markers were quantified using enzyme-linked immunosorbent assay (ELISA) with commercially available kits (R&D Systems).

    Techniques: Comparison

    Fig. 5 CXCL12 regulates CD8+ T-cell infiltration after SAH. A: Representative flow cytometric profiles of CD8+ and CD4+ T cells from the cerebral cortex across different groups. The gating strategy is provided in Supplementary Data 1. B: Immunofluorescence staining for CD8+CXCR4+ cells around the cerebral cortex across different groups. Scale bar = 50 μm. C-D: Quantification of CD8+ and CD4+ T cells (n = 6). E: Quantification of CD8+CXCR4+ cells (n = 6). Saline refers to the vehicle-treated control group; CXCL12 refers to the group treated with recombinant CXCL12 protein; CXCL12 Ab indicates the group treated with a CXCL12 neutralizing antibody; and CXCL12 + AMD3100 represents the group cotreated with recombinant CXCL12 and the CXCR4 antagonist AMD3100. **p < 0.01, ****p < 0.0001. ns indicates no significance (p > 0.05)

    Journal: Journal of neuroinflammation

    Article Title: Single-cell sequencing reveals intracranial microvasculature-derived CXCL12 promotes CD8 + T-cell infiltration and blood-brain barrier dysfunction after subarachnoid hemorrhage in mice.

    doi: 10.1186/s12974-025-03444-0

    Figure Lengend Snippet: Fig. 5 CXCL12 regulates CD8+ T-cell infiltration after SAH. A: Representative flow cytometric profiles of CD8+ and CD4+ T cells from the cerebral cortex across different groups. The gating strategy is provided in Supplementary Data 1. B: Immunofluorescence staining for CD8+CXCR4+ cells around the cerebral cortex across different groups. Scale bar = 50 μm. C-D: Quantification of CD8+ and CD4+ T cells (n = 6). E: Quantification of CD8+CXCR4+ cells (n = 6). Saline refers to the vehicle-treated control group; CXCL12 refers to the group treated with recombinant CXCL12 protein; CXCL12 Ab indicates the group treated with a CXCL12 neutralizing antibody; and CXCL12 + AMD3100 represents the group cotreated with recombinant CXCL12 and the CXCR4 antagonist AMD3100. **p < 0.01, ****p < 0.0001. ns indicates no significance (p > 0.05)

    Article Snippet: Administration of a CXCL12 neutralizing antibody, the CXCR4 antagonist AMD3100, or recombinant CXCL12 protein To intervene in CXCL12-CXCR4 signaling, the mice were intravenously administered a CXCL12 neutralizing antibody (MAB310-100, R&D Systems, Shanghai, China).

    Techniques: Immunofluorescence, Staining, Saline, Control, Recombinant

    Fig. 6 CXCL12 regulates CD8⁺ T-cell cytotoxicity and brain edema. A: Western blot analysis showing granzyme B and perforin expression in the cerebral cortex of the sham, saline, CXCL12 Ab, CXCL12, and CXCL12 + AMD3100 groups. B, C: Quantification of granzyme B (n = 5) and perforin expression (n = 6). D: Measurement of brain water content in the bilateral cerebral hemispheres and cerebellum across groups (n = 6). Saline refers to the vehicle-treated control group; CXCL12 refers to the group treated with recombinant CXCL12 protein; CXCL12 Ab indicates the group treated with a CXCL12 neutralizing antibody; and CXCL12 + AMD3100 represents the group cotreated with recombinant CXCL12 and the CXCR4 antagonist AMD3100. *p < 0.05, ***p < 0.001, ****p < 0.0001. ns indicates no significance (p > 0.05)

    Journal: Journal of neuroinflammation

    Article Title: Single-cell sequencing reveals intracranial microvasculature-derived CXCL12 promotes CD8 + T-cell infiltration and blood-brain barrier dysfunction after subarachnoid hemorrhage in mice.

    doi: 10.1186/s12974-025-03444-0

    Figure Lengend Snippet: Fig. 6 CXCL12 regulates CD8⁺ T-cell cytotoxicity and brain edema. A: Western blot analysis showing granzyme B and perforin expression in the cerebral cortex of the sham, saline, CXCL12 Ab, CXCL12, and CXCL12 + AMD3100 groups. B, C: Quantification of granzyme B (n = 5) and perforin expression (n = 6). D: Measurement of brain water content in the bilateral cerebral hemispheres and cerebellum across groups (n = 6). Saline refers to the vehicle-treated control group; CXCL12 refers to the group treated with recombinant CXCL12 protein; CXCL12 Ab indicates the group treated with a CXCL12 neutralizing antibody; and CXCL12 + AMD3100 represents the group cotreated with recombinant CXCL12 and the CXCR4 antagonist AMD3100. *p < 0.05, ***p < 0.001, ****p < 0.0001. ns indicates no significance (p > 0.05)

    Article Snippet: Administration of a CXCL12 neutralizing antibody, the CXCR4 antagonist AMD3100, or recombinant CXCL12 protein To intervene in CXCL12-CXCR4 signaling, the mice were intravenously administered a CXCL12 neutralizing antibody (MAB310-100, R&D Systems, Shanghai, China).

    Techniques: Western Blot, Expressing, Saline, Control, Recombinant

    Fig. 9 Neutralizing CXCL12 promoted neurobehavioral recovery in mice after SAH. A: Representative electron microscopy images showing ultrastructural changes in the brain cortex after SAH. Yellow arrows indicate mitochondrial damage, and red arrows indicate myelin damage. Scale bar = 2 μm. B: Representative images of the open field test. C: Quantification of the G ratio (n = 4). D: Quantification of movement trajectory distances (n = 6). E: Beam balance scores measured across groups (n = 6). F: Modified Garcia score measured across groups (n = 6). Saline refers to the vehicle-treated control group; CXCL12 refers to the group treated with recombinant CXCL12 protein; CXCL12 Ab indicates the group treated with a CXCL12 neutralizing antibody; and CXCL12 + AMD3100 represents the group cotreated with recombinant CXCL12 and the CXCR4 antagonist AMD3100. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

    Journal: Journal of neuroinflammation

    Article Title: Single-cell sequencing reveals intracranial microvasculature-derived CXCL12 promotes CD8 + T-cell infiltration and blood-brain barrier dysfunction after subarachnoid hemorrhage in mice.

    doi: 10.1186/s12974-025-03444-0

    Figure Lengend Snippet: Fig. 9 Neutralizing CXCL12 promoted neurobehavioral recovery in mice after SAH. A: Representative electron microscopy images showing ultrastructural changes in the brain cortex after SAH. Yellow arrows indicate mitochondrial damage, and red arrows indicate myelin damage. Scale bar = 2 μm. B: Representative images of the open field test. C: Quantification of the G ratio (n = 4). D: Quantification of movement trajectory distances (n = 6). E: Beam balance scores measured across groups (n = 6). F: Modified Garcia score measured across groups (n = 6). Saline refers to the vehicle-treated control group; CXCL12 refers to the group treated with recombinant CXCL12 protein; CXCL12 Ab indicates the group treated with a CXCL12 neutralizing antibody; and CXCL12 + AMD3100 represents the group cotreated with recombinant CXCL12 and the CXCR4 antagonist AMD3100. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

    Article Snippet: Administration of a CXCL12 neutralizing antibody, the CXCR4 antagonist AMD3100, or recombinant CXCL12 protein To intervene in CXCL12-CXCR4 signaling, the mice were intravenously administered a CXCL12 neutralizing antibody (MAB310-100, R&D Systems, Shanghai, China).

    Techniques: Electron Microscopy, Modification, Saline, Control, Recombinant

    Fig. 10 Schematic illustration of the present study. After SAH (red arrow), endothelial cells and pericytes secrete CXCL12 (yellow arrow), facilitating the infiltration of CD8+ CXCR4+ T cells into the brain parenchyma (green arrow). These infiltrating T cells release perforin and granzyme B (purple arrow), inducing endothelial cell apoptosis and exacerbating BBB disruption. Blocking CXCL12-mediated T-cell infiltration with CXCL12 antibodies or AMD3100 (a CXCR4 antagonist, blue arrow) preserves BBB integrity and promotes neurological outcomes after SAH

    Journal: Journal of neuroinflammation

    Article Title: Single-cell sequencing reveals intracranial microvasculature-derived CXCL12 promotes CD8 + T-cell infiltration and blood-brain barrier dysfunction after subarachnoid hemorrhage in mice.

    doi: 10.1186/s12974-025-03444-0

    Figure Lengend Snippet: Fig. 10 Schematic illustration of the present study. After SAH (red arrow), endothelial cells and pericytes secrete CXCL12 (yellow arrow), facilitating the infiltration of CD8+ CXCR4+ T cells into the brain parenchyma (green arrow). These infiltrating T cells release perforin and granzyme B (purple arrow), inducing endothelial cell apoptosis and exacerbating BBB disruption. Blocking CXCL12-mediated T-cell infiltration with CXCL12 antibodies or AMD3100 (a CXCR4 antagonist, blue arrow) preserves BBB integrity and promotes neurological outcomes after SAH

    Article Snippet: Administration of a CXCL12 neutralizing antibody, the CXCR4 antagonist AMD3100, or recombinant CXCL12 protein To intervene in CXCL12-CXCR4 signaling, the mice were intravenously administered a CXCL12 neutralizing antibody (MAB310-100, R&D Systems, Shanghai, China).

    Techniques: Disruption, Blocking Assay